Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start (scientific article published on 31 October 2013)

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

Q54571477

All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population

Q57794046

Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program

Q57832324

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

Q59151059

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

Q22242768

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Q24597052

Prevention of HIV-1 infection with early antiretroviral therapy

Q24634688

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Q24656950

Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort

Q28477027

Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis

Q28742423

Rising population cost for treating people living with HIV in the UK, 1997-2013

Q28743848

Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006

Q28744286

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

Q29305377

Effect of early versus deferred antiretroviral therapy for HIV on survival

Q33789114

HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy

Q34203609

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Q34289633

Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.

Q34464437

The survival benefits of AIDS treatment in the United States

Q34533291

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries

Q35057962

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States

Q35214966

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults

Q35610449

Contemporary costs of HIV healthcare in the HAART era

Q36550975

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial

Q36627942

Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States

Q36875336

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

Q36948710

Diagnosed and undiagnosed HIV-infected populations in Europe

Q37192553

Long-term trends in adherence to antiretroviral therapy from start of HAART.

Q38445883

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

Q38959219

Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers

Q41252333

P433

issue

P304

page(s)

165-174

P577

publication date

2013-10-31

P1433

published in

HIV Medicine

Q15756376

P1476

title

Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start

P478

volume

Reverse relations

cites work (P2860)

Q40743211	A Regional Drug and Therapeutics Committee-led Intervention to Reduce the Hospital Costs of Expensive HIV Drugs.
Q58092550	A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV
Q47644937	Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection
Q34273315	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
Q36303488	Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
Q35761213	Evidence of High Out of Pocket Spending for HIV Care Leading to Catastrophic Expenditure for Affected Patients in Lao People's Democratic Republic
Q36234850	HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy
Q36206941	Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens
Q35741765	New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy)